步长制药：控股子公司拟签署技术转让开发合同

Core Viewpoint - The announcement indicates that the company, Buchang Pharma, is entering into a technology transfer agreement with Shandong University of Traditional Chinese Medicine Affiliated Hospital for the development of a new traditional Chinese medicine aimed at treating specific health conditions [1] Group 1: Company Developments - Buchang Pharma's subsidiary, Shandong Danhong, plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital [1] - The total price for the technology transfer of the traditional Chinese medicine "Erzhi Tiaojing Optimized Formula" is set at 15 million yuan [1] - The collaboration aims to develop a Class 1 new drug for treating conditions related to kidney deficiency and ovarian reserve function decline [1] Group 2: Research and Development - The parties will conduct research on the new traditional Chinese medicine and aim to obtain a national drug registration certificate [1] - Successful development will lead to industrial-scale production of the new drug [1]